Anti-Rejection Drug May Boost Diabetes In Kidney Transplant Patients; Those Treated With Wyeth’s Sirolimus Faced Up To 66% Increased Risk Of Disease After Operation, University of British Columbia Study

HealthDay News -- Treatment with the anti-rejection drug sirolimus may lead to increased risk of diabetes in kidney transplant patients, say researchers who analyzed data on about 20,000 Medicare patients who had kidney transplants between 1995 and 2003.